Journal
BLOOD CANCER JOURNAL
Volume 11, Issue 6, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41408-021-00497-1
Keywords
-
Categories
Funding
- K12 Paul Calabresi Clinical Scholarship Award [NIH/NCI K12 CA088084]
Ask authors/readers for more resources
AML with IDH mutations can be effectively treated with selective oral inhibitors of mutant IDH1 and IDH2. Research is currently focusing on combining IDH inhibitors with standard therapies and other targeted therapies to further enhance clinical efficacy.
Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy; approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2. These recurrent mutations in key metabolic enzymes lead to the production of the oncometabolite 2-hydroxyglutarate, which promotes leukemogenesis through a block in normal myeloid differentiation. Since this discovery, selective oral inhibitors of mutant IDH1 and IDH2 have subsequently been developed and are now approved as single agent therapy, based on clinical efficacy observed within the original first-in-human trials. The investigation of IDH inhibitors in combination with standard therapies such as azacytidine, with intensive chemotherapy, and with other small molecule targeted therapies in rational combinations are currently under evaluation to further improve upon clinical efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available